Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial
BackgroundPancreatic adenocarcinoma carries a grim prognosis, and there are few recognized effective second-line treatment strategies. We attempted to evaluate the efficacy and safety of a combination of S-1, sintilimab, and anlotinib as a second-line treatment in pancreatic cancer patients with liv...
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2024-02-01
|
| Serier: | Frontiers in Immunology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1210859/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|